RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNXT RenovoRx Inc

Closed Good Friday 04-17 16:00:00 EDT

1.02

-0.01

-0.97%

盘后1.02

+0.000.00%

19:53 EDT

High1.04	Low0.9800	Vol109.22K
Open1.03	D1 Closing1.03	Amplitude5.83%
Mkt Cap37.28M	Tradable Cap35.71M	Total Shares36.55M
T/O110.58K	T/O Rate0.31%	Tradable Shares35.01M
P/B8.32	ROE-1192.69%	EPS-0.40
52wk High1.69	52wk Low0.7500	P/E-2.58
Dividend0.00	Div.Yield0.00	ROA-143.08%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"RNXT","market":"US","secType":"STK","nameCN":"RenovoRx Inc","latestPrice":1.02,"timestamp":1744920000000,"preClose":1.03,"halted":0,"volume":109217,"hourTrading":{"tag":"盘后","latestPrice":1.02,"preClose":1.02,"latestTime":"19:53 EDT","volume":6,"amount":6.0004,"timestamp":1744934021797},"delay":0,"floatShares":35014408,"shares":36546752,"eps":-0.395758,"marketStatus":"Closed Good Friday","change":-0.01,"latestTime":"04-17 16:00:00 EDT","open":1.03,"high":1.04,"low":0.98,"amount":110583.61047760001,"amplitude":0.058252,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.395758,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":1.03,"preHourTrading":{"tag":"盘前","latestPrice":1.04,"preClose":1.03,"latestTime":"09:25 EDT","volume":3203,"amount":3320.200973,"timestamp":1744896300037},"postHourTrading":{"tag":"盘后","latestPrice":1.02,"preClose":1.02,"latestTime":"19:53 EDT","volume":6,"amount":6.0004,"timestamp":1744934021797},"volumeRatio":0.5737295866618951},"requestUrl":"/m/hq/s/RNXT","defaultTab":"news","newsList":[{"id":"2528700634","title":"RenovoRx CMO Makes Bold Stock Purchase!","url":"https://stock-news.laohu8.com/highlight/detail?id=2528700634","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528700634?lang=en_us&edition=full_marsco","pubTime":"2025-04-18 10:02","pubTimestamp":1744941754,"startTime":"0","endTime":"0","summary":"New insider activity at RenovoRx ( ($RNXT) ) has taken place on April 18, 2025. CMO Ramtin Agah has made a significant investment by purchasing 15,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/renovorx-cmo-makes-bold-stock-purchase-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/renovorx-cmo-makes-bold-stock-purchase-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT","BK4139","BK4539"],"gpt_icon":0},{"id":"2527117202","title":"BRIEF-Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community","url":"https://stock-news.laohu8.com/highlight/detail?id=2527117202","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527117202?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 20:43","pubTimestamp":1744807395,"startTime":"0","endTime":"0","summary":"BRIEF-Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology CommunityApril 16 (Reuters) - RenovoRx Inc RNXT.O:RENOVORX INCREASES U.S. PRODUCTION OF RENOVOCATH D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA8TVTYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2527217584","title":"RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community","url":"https://stock-news.laohu8.com/highlight/detail?id=2527217584","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527217584?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 20:30","pubTimestamp":1744806600,"startTime":"0","endTime":"0","summary":"RenovoCath is proudly made in America at a facility in North Barrington, IL. RenovoRx management and board members purchased over 140,000 shares of RenovoRx stock during recent open trading window, signaling their confidence in RenovoRx’s future. \"As we anticipated, we are seeing growing demand for our proprietary RenovoCath device. We expect first-quarter 2025 revenue from RenovoCath to reach the low six-figure range, with continued sequential growth quarter-over-quarter throughout the remainder of the year,\" said Shaun Bagai, Chief Executive Officer of RenovoRx. \"We estimate that our initial total addressable market for RenovoCath is approximately $400 million in peak annual U.S. sales. We further believe we can capture this market over time with a very small sales force and/or distribution partners, which will keep our operating expenses low and put us on a path to cash flow positive operations. We are proud to manufacture RenovoCath in the U.S. and will continue to increase product","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-increases-u-production-renovocath-123000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNXT","BK4539","BK4017","IAG","BK4139"],"gpt_icon":0},{"id":"2526571970","title":"Top Executives Make Bold Moves with RenovoRx Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2526571970","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526571970?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 10:01","pubTimestamp":1744336868,"startTime":"0","endTime":"0","summary":"New insider activity at RenovoRx ( ($RNXT) ) has taken place on April 11, 2025. In recent transactions, Ron Kocak, the VP Controller and PAO, acqui...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-make-bold-moves-with-renovorx-stock-purchases?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-make-bold-moves-with-renovorx-stock-purchases?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2526375469","title":"RenovoRx CMO Makes a Bold Move with Major Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2526375469","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526375469?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 10:01","pubTimestamp":1744250510,"startTime":"0","endTime":"0","summary":"New insider activity at RenovoRx ( ($RNXT) ) has taken place on April 10, 2025. CMO Ramtin Agah has made a significant investment in RenovoRx by pu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/renovorx-cmo-makes-a-bold-move-with-major-stock-purchase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/renovorx-cmo-makes-a-bold-move-with-major-stock-purchase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","RNXT"],"gpt_icon":0},{"id":"2524041277","title":"RenovoRx Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524041277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524041277?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 18:36","pubTimestamp":1743762960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNXT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 04, 2025 06:36 ET (10:36 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2524124897","title":"RenovoRx Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524124897","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524124897?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 05:02","pubTimestamp":1743541330,"startTime":"0","endTime":"0","summary":"RenovoRx Inc reports results for the quarter ended December 31 - Earnings SummaryRenovoRx Inc RNXT.OQ reported a quarterly adjusted loss of 13 cents per share for the quarter ended December 31, higher","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nL5N3QF1RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2524890689","title":"RenovoRx Delays Yearly Report Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524890689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524890689?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 06:27","pubTimestamp":1743460025,"startTime":"0","endTime":"0","summary":"RenovoRx ( ($RNXT) ) has released a notification of late filing. RenovoRx, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-delays-yearly-report-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-delays-yearly-report-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2523582638","title":"RenovoRx Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523582638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523582638?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:24","pubTimestamp":1743193455,"startTime":"0","endTime":"0","summary":"RenovoRx Inc  expected to post a loss of10cents a share - Earnings Preview RenovoRx Inc RNXT.OQ RNXT.O is expected to show no change in quarterly revenue when it reports  results on April 1 (estimated","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB1R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2522737205","title":"RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522737205","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522737205?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":"Data supports the novel Trans-Arterial Micro-Perfusion  therapy platform for targeted chemotherapy delivery for the potential to minimize a therapy’s toxicities versus systemic intravenous therapies. Data shows localized, intra-arterial delivery of gemcitabine with FDA-cleared RenovoCath device  resulted in lower systemic levels of drug compared to intravenous delivery of gemcitabine. MOUNTAIN VIEW, Calif., March 28, 2025----RenovoRx, Inc.  , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, announced today that a new human pharmacokinetic  data abstract was presented at the Society of Surgical Oncology  2025 Annual Meeting on March 27 – 29, 2025 in Tampa, FL: ePoster P379.PK analyses were performed on 19 patients with locally advanced pancreatic cancer receiving IAG from six sites as part of the TIGeR-PaC trial. In this analysis, localized, dual-balloon catheter-mediated IAG resulted in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-highlights-human-pharmacokinetic-data-120000855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNXT","BK4017","BK4218","BK4139","BK4181","BK4588","SSO","PK","BK4539","IAG","BK4585"],"gpt_icon":0},{"id":"2522374602","title":"HC Wainwright Initiates Coverage on RenovoRx With Buy Rating, $3 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374602","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374602?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:51","pubTimestamp":1743076307,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Coverage on RenovoRx With Buy Rating, $3 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RNXT"],"gpt_icon":0},{"id":"2522432974","title":"RenovoRx, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522432974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522432974?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:04","pubTimestamp":1743069885,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nAZN3MNL1P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2522874424","title":"RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522874424","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522874424?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:00","pubTimestamp":1742990400,"startTime":"0","endTime":"0","summary":"Peer-reviewed paper will be honored as a Journal of Vascular and Interventional Radiology Award-Winning Paper. Pre-clinical data show that TAMP increases intra-arterial pressure, improving drug delivery with 100-fold increase in local tissue concentration of the therapy. TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of existing and new treatments. MOUNTAIN VIEW, Calif., March 26, 2025----RenovoRx, Inc.  , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, is proud to announce that a publication supporting the Company’s proprietary Trans-Arterial Micro-Perfusion  therapy platform for targeted locoregional drug delivery will be recognized in the Journal of Vascular and Interventional Radiology  Award-Winning Paper Scientific Session during the upcoming Society of Interventional Radiology  2025 Annual Scientific Meeting.Currently, most cancer pati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-pre-clinical-results-supporting-120000332.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","RNXT","SIR","IAG","BK4539","BK4017"],"gpt_icon":0},{"id":"2520945390","title":"RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3Rd at 12:00 P.m. Et","url":"https://stock-news.laohu8.com/highlight/detail?id=2520945390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520945390?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:00","pubTimestamp":1742472003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUA4RQ2PX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2520245746","title":"RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2520245746","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520245746?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"Shaun Bagai to discuss the momentum of RenovoRx’s commercialization efforts for its RenovoCath device, including an update on initial revenues generated, and continued progress on the ongoing Phase III TIGeR-PaC clinical trial. MOUNTAIN VIEW, Calif., March 20, 2025----RenovoRx, Inc.  , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that it will host a fireside chat with Shaun Bagai, Chief Executive Officer, on Thursday, April 3, 2025, at 12:00 p.m. ET.Mr. Bagai will discuss RenovoRx’s continued momentum of its RenovoCath commercial efforts, including new purchase orders and reorders received from cancer center customers, and the realization of initial revenues.Mr. Bagai will also discuss progress on RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluating the Company’s lead drug-device combination product candidate , known as IAG which uses the pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-ceo-strategic-during-fireside-120000971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","BK4017","BK4585","RNXT","BK4561","BK4581","BK4588","ET","IAG","BK4139","BK4590","BK4539"],"gpt_icon":0},{"id":"2514837819","title":"RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837819","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837819?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"Initial Revenues Expected this Quarter, and Customer Pipeline for RenovoCath Standalone Device Continues to Expand, Including High Volume National Cancer Institute-Designated Centers. RenovoCath Gaining Validation in an Initial U.S. Market Estimated at $400 Million Annually. MOUNTAIN VIEW, Calif., February 26, 2025----RenovoRx, Inc.  , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced continuing momentum with the Company’s RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers.Additionally, RenovoRx reported that utilization of RenovoCath devices by its initial customers announced this past December has led to repeat purchase orders. Together, these announcements demonstrate that RenovoRx is continuing on the path to initial revenue generation from RenovoCath sales this quarter and that r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-advances-commercialization-renovocath-several-130000780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2511547441","title":"RenovoRx presents data from Trans-Arterial Micro-Perfusion therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2511547441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511547441?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 21:27","pubTimestamp":1739453248,"startTime":"0","endTime":"0","summary":"RenovoRx (RNXT) highlighted its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conference in Las Vegas, Nevada....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-presents-data-from-trans-arterial-micro-perfusion-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-presents-data-from-trans-arterial-micro-perfusion-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","RNXT"],"gpt_icon":0},{"id":"2510807009","title":"RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2510807009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510807009?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 20:00","pubTimestamp":1739275206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUAFKB4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2509621799","title":"RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2509621799","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509621799?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 16:11","pubTimestamp":1738915913,"startTime":"0","endTime":"0","summary":"RenovoRx  announced the pricing of an underwritten public offering, aiming to raise approximately $12.1 million through the sale of 11,523,810 shares of its common stock at $1.05 per share.GuruFocus has detected 2 Warning Signs with RNXT.Apart from the advancement of its Phase III TIGeR-PaC trial and the development of commercial sales and marketing operations for RenovoCath as a standalone device, the business intends to utilize the net proceeds for working capital and other corporate reasons. Subject to usual closing conditions, the offering is scheduled to conclude on Feb. 10.The shares of RenovoRx fell after the news. Down 2%, from the previous closing, the stock was valued at $1.46 as of the market close on Feb. 6. The shares dropped even further in after-hours trading24.6%to hit $1.10.The bookrunner for the offering is Titan Partners Group, a branch of American Capital Partners.RenovoRx is a life sciences firm with an eye on creating tailored cancer treatments and commercializing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-prices-12-1-million-081153521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNXT","POST","BK4139","BK4212","BK4539"],"gpt_icon":0},{"id":"2509275354","title":"RenovoRx 11.52M share Spot Secondary priced at $1.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275354?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 10:00","pubTimestamp":1738893631,"startTime":"0","endTime":"0","summary":"The deal priced below last closing price of $1.46. Titan Partners is acting as sole book running manager for the offering. Published first on TheFl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-11-52m-share-spot-secondary-priced-at-1-05?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-11-52m-share-spot-secondary-priced-at-1-05?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovorx.com","stockEarnings":[{"period":"1week","weight":0.2895},{"period":"1month","weight":0.0572},{"period":"3month","weight":-0.32},{"period":"6month","weight":0.02},{"period":"1year","weight":-0.1429},{"period":"ytd","weight":-0.2093}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.121404},{"month":2,"riseRate":0.75,"avgChangeRate":0.165499},{"month":3,"riseRate":0,"avgChangeRate":-0.152336},{"month":4,"riseRate":0.25,"avgChangeRate":-0.149653},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.09114},{"month":6,"riseRate":0.666667,"avgChangeRate":0.066465},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.026625},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.08395},{"month":9,"riseRate":0.25,"avgChangeRate":-0.143321},{"month":10,"riseRate":0,"avgChangeRate":-0.119349},{"month":11,"riseRate":0.75,"avgChangeRate":0.078757},{"month":12,"riseRate":0.75,"avgChangeRate":0.620654}],"exchange":"NASDAQ","name":"RenovoRx Inc","nameEN":"RenovoRx Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RenovoRx Inc,RNXT,RenovoRx Inc股票,RenovoRx Inc股票老虎,RenovoRx Inc股票老虎国际,RenovoRx Inc行情,RenovoRx Inc股票行情,RenovoRx Inc股价,RenovoRx Inc股市,RenovoRx Inc股票价格,RenovoRx Inc股票交易,RenovoRx Inc股票购买,RenovoRx Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}